Eon

Lithium South Developing High-Value Alternatives in Lithium Production

Retrieved on: 
Monday, April 8, 2024
Lithium, Lithium chloride, National Instrument 43-101, Eon, Laboratory, National instrument, Lithium carbonate

The first option yielded a super-concentrated Lithium Chloride (LiCl) brine containing 6% lithium content by mass, demonstrating a cumulative lithium recovery of 67% after pre-concentration and concentration evaporation stages.

Key Points: 
  • The first option yielded a super-concentrated Lithium Chloride (LiCl) brine containing 6% lithium content by mass, demonstrating a cumulative lithium recovery of 67% after pre-concentration and concentration evaporation stages.
  • In the second option, Lithium South successfully produced a bulk lithium carbonate (Li2CO3) product, showing potential for purification to battery grade quality.
  • "Exploring these innovative production methods allows us to future-proof our project and potentially tap into more lucrative markets," said Adrian F. C. Hobkirk, Founder and CEO of Lithium South.
  • Lithium South Development remains committed to advancing its HMN Li Project, leveraging both traditional and innovative methods to ensure sustainable, efficient, and high-quality lithium production.

Mountain Valley MD Provides Business Update, Appoints New CFO

Retrieved on: 
Friday, March 1, 2024
Biotechnology, Health, Pharmaceutical, Vitamins, Supplements, Agriculture, Natural Resources, Research, Fitness & Nutrition, Environment, Science, Veterinary, Deep Sleep, Animal, Growth, Commerce, Sale, Powder, Climate change, HLB, Eon, Farm, MVDM, Livestock, McGill University, Micronutrient, Plant, GMP, Tree, Eons.com, Nutraceutical, Immunity, Tablet, Photosynthesis, CW, CPA, FRA, Sleep, Calendar, Tilapia, Logic, Catfish, CFO, Ivermectin, Aquaculture, Fishery, Patent, Consultant, Biomass, Government, Licensee, Nutrient, Republic, Cognition, Citrus, Disease

The MVMD team and our extensive network of partners has made significant progress advancing our commercialization priorities,” stated Dennis Hancock, President & CEO of Mountain Valley MD.

Key Points: 
  • The MVMD team and our extensive network of partners has made significant progress advancing our commercialization priorities,” stated Dennis Hancock, President & CEO of Mountain Valley MD.
  • To date, the Company has worked on a range of formulations for Quicksome™-powered product applications, including sleep, energy, appetite suppressant, cognition, immunity, calm, and pain relief.
  • The Company believes this will be valuable in its business development efforts and broad growth plans for its nutraceutical line of business.
  • Since July 2009, his tenure at Malaspina Consultants Inc. has been marked by CFO and accounting roles for various public and private companies across multiple industries.

Roswell Park Comprehensive Cancer Center Expands Lung Cancer Screening Program by Leveraging AI Software to Track and Manage Eligible Patients

Retrieved on: 
Wednesday, March 6, 2024
Lung cancer, AI, LCS, Radiology, Eon, National Cancer Institute, Communication, Survival rate, American Lung Association, Health, Patient, EPM, Concurrent estate, Medical imaging

According to the American Lung Association, 44% of lung cancer cases are not caught until a late stage, when the survival rate is only 8%.

Key Points: 
  • According to the American Lung Association, 44% of lung cancer cases are not caught until a late stage, when the survival rate is only 8%.
  • In leveraging Eon Patient Management (EPM) to longitudinally track and manage lung cancer screening patients, Roswell Park will be able to improve outcomes by ensuring more patients return for guideline-driven follow-up care.
  • Eon's lung cancer screening (LCS) patient management platform uses advanced AI to automate routine administrative tasks, without interrupting radiology workflows.
  • As the only National Cancer Institute-designated comprehensive cancer center in Upstate New York, we must ensure we have superior solutions in place to provide patients with the best care."

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

Retrieved on: 
Friday, January 19, 2024
EON, RNA-Seq, Oligonucleotide, Knowledge, RNA, Science, Circulatory system, Mouse, NHP, NTCP, ACTB, Cholestasis, ANGPTL3, Cardiovascular disease, Plasma, Conference, B4GALT1, LDL, Liver, Eon, ProQR, ADAR, Nested polymerase chain reaction, CNS, Video game

“We were pleased to present new in vivo data for our proprietary Axiomer RNA editing technology platform at the Deaminet 2024 meeting, demonstrating robust editing of ACTB in the liver of NHP, as well as functional protein data with the liver target ANGPTL3 in mice,” said Gerard Platenburg, Chief Scientific Officer of ProQR.

Key Points: 
  • “We were pleased to present new in vivo data for our proprietary Axiomer RNA editing technology platform at the Deaminet 2024 meeting, demonstrating robust editing of ACTB in the liver of NHP, as well as functional protein data with the liver target ANGPTL3 in mice,” said Gerard Platenburg, Chief Scientific Officer of ProQR.
  • “To date, we have generated robust in vitro and in vivo preclinical platform data across a range of liver and CNS targets.
  • Presentation of new data highlighting up to 70% editing efficiency of ACTB in liver of mice and NHPs at multiple timepoints.
  • These new preclinical platform data further highlight the potential of Axiomer EONs in preparation for clinical development and supporting discovery of potential new therapeutic applications.

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

Retrieved on: 
Friday, January 5, 2024
RNA, Methyl group, Partnership, Rett syndrome, Research, ProQR, UC, Eon, RSRT, CNS, University of California, Davis, MECP2, Pharmaceutical industry

“The Rett Syndrome Research Trust is the leading patient advocacy group championing a cure for Rett syndrome and we look forward to collaborating with them to further expand the broad applicability of our Axiomer RNA editing technology to Rett syndrome, a rare neurodevelopment disorder with significant unmet medical need,” said Daniel A. de Boer, Chief Executive Officer of ProQR.

Key Points: 
  • “The Rett Syndrome Research Trust is the leading patient advocacy group championing a cure for Rett syndrome and we look forward to collaborating with them to further expand the broad applicability of our Axiomer RNA editing technology to Rett syndrome, a rare neurodevelopment disorder with significant unmet medical need,” said Daniel A. de Boer, Chief Executive Officer of ProQR.
  • “Axiomer has the potential to restore precise levels of the MECP2 protein, which is lacking in Rett syndrome.
  • It is the intent of the partnership to be continued by an expanded co-funding arrangement following the initial discovery work.
  • The co-funding of the next phase of the collaboration would enable clinical development of an Axiomer-based therapeutic for Rett syndrome MECP2.

BP-FLAC launched the PoW side-chain called Eon, paving the way for the next AI era

Retrieved on: 
Tuesday, December 19, 2023
Bitcoin, EON, CUDA, Prisoner of war, News, Mining, ZK, Decentralized finance, RTX, Eon, Nifedipine, AI, Privacy, Marketplace, NFT, A100, WOD, Algorithm, Cryptocurrency

CEO Alexandrine envisions BP-FLAC meeting the AI service needs of 200 million users, solidifying its leadership in blockchain AI.

Key Points: 
  • CEO Alexandrine envisions BP-FLAC meeting the AI service needs of 200 million users, solidifying its leadership in blockchain AI.
  • Recently, BP-FLAC launched the side PoW chain called Eon.
  • Limited Supply and Mining Mechanism:
    Eon adopts a PoW consensus mechanism, capping the total token supply at 1 billion with a 20-year mining period.
  • This focus positions Eon as a foundational infrastructure provider for the impending AI era, leveraging blockchain technology to enable and advance AI applications.

AI technology helps Geisinger in fight against lung cancer

Retrieved on: 
Wednesday, November 1, 2023
Lung cancer, Eon, Radiology, Patient, Health, Partnership, Medical imaging, Nursing

DANVILLE, Pa. , Nov. 1, 2023 /PRNewswire/ -- Geisinger has begun using a new patient management system to expand its ability to identify and manage patients with incidentally identified lung abnormalities, as well as manage those eligible for lung cancer screening.

Key Points: 
  • DANVILLE, Pa. , Nov. 1, 2023 /PRNewswire/ -- Geisinger has begun using a new patient management system to expand its ability to identify and manage patients with incidentally identified lung abnormalities, as well as manage those eligible for lung cancer screening.
  • In 2020, Geisinger implemented the STAIR™ Program (which stands for System to Track Abnormalities of Importance Reliably) to help manage these patients.
  • The new patient management technology, in partnership with Denver-based health company Eon, automatically enrolls patients with an incidental finding in the STAIR program.
  • "The STAIR program and lung cancer screening program are two important ways that we can catch cancer earlier when the patient has a chance to be cured," Dr. Mehta said.

Mountain Valley MD Provides Business Update

Retrieved on: 
Thursday, August 10, 2023
Health, Clinical Trials, General Health, Research, Science, Biotechnology, GMP, Communication, Fertilizer, Refrigeration, IVM, Temperature, Solubility, OF, Logic, Transport, Environment, Toxicity, Consultant, Biomass, Population growth, Photosynthesis, Eurasian carp, CSE, Overalls, AC, OMRI, FRA, Government, Climate change, Animal, Water, Contract research organization, Mortality, Drug, Lead, Agriculture, Calendar, Nutrient, Eon, Sale, Republic, Licensee, Fishery, Video game, Property management, Pharmaceutical industry, Ivermectin, Charaxes agrarius, Tilapia, Circadian rhythm, LATAM

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to provide a business update and details of its current progress.

Key Points: 
  • Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) is pleased to provide a business update and details of its current progress.
  • “The MVMD team and our extensive network of partners has been making significant progress on our commercialization objectives,” stated Dennis Hancock, President & CEO of Mountain Valley MD.
  • MVMD is currently conducting business development activity in Mexico, Central America, South America, and the United States of America.
  • The initial business development and Agrarius product registration processes are focused on Colombia, Brazil, Uruguay, Panama and Mexico.

Healthtech Leader Eon Announces 1MM Patients Impacted by Their Incidental Findings and Screening Software

Retrieved on: 
Wednesday, May 24, 2023
LifePoint Health, Communication, Hospital Sisters Health System, Cleveland Clinic, Eon, Friends, Parent, Survival, Cancer, Lung cancer, Liver, Intelligence, Field triage, Hospital, Medical Education Number, AAA, Patient, EPM, Risk, UCHealth, Growth, System, Pancreas, Health, HCA Healthcare, Linguistics, Data science, Medical imaging, Nursing, Breast

DENVER, May 24, 2023 /PRNewswire/ -- Eon , a leading provider of incidental findings and screening patient management software, announced today that it has surpassed 1MM patients impacted by their proprietary AI software and services.

Key Points: 
  • DENVER, May 24, 2023 /PRNewswire/ -- Eon , a leading provider of incidental findings and screening patient management software, announced today that it has surpassed 1MM patients impacted by their proprietary AI software and services.
  • He knew that by tracking patients with lung nodules found early on regular radiology exams, he could diagnose lung cancer at earlier stages.
  • Eon also offers a tech-enabled care navigation service that helps hospital care teams offload administrative tasks and reach more patients.
  • These million patients represent our neighbors, brothers, sisters, parents and friends," said Dr. Scott Skibo, Chief Medical Officer at Eon Health.

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

Retrieved on: 
Tuesday, May 9, 2023
EON, SAR, ABR, Eon, RNA, ADAR, Mouse, Liver, DZ, EER, ProQR, Oligonucleotide, Fine chemical

ProQR Therapeutics NV.

Key Points: 
  • ProQR Therapeutics NV.
  • (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced a presentation at the Oligonucleotide and Peptide Therapeutics conference (TIDES USA), May 7-10, 2023 in San Diego, CA, USA.
  • 50% editing in liver of mice.
  • New optimizations are being evaluated (not disclosed in the presentation).